BR112012010186B8 - derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos - Google Patents

derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos

Info

Publication number
BR112012010186B8
BR112012010186B8 BR112012010186A BR112012010186A BR112012010186B8 BR 112012010186 B8 BR112012010186 B8 BR 112012010186B8 BR 112012010186 A BR112012010186 A BR 112012010186A BR 112012010186 A BR112012010186 A BR 112012010186A BR 112012010186 B8 BR112012010186 B8 BR 112012010186B8
Authority
BR
Brazil
Prior art keywords
heteroaryl derivatives
pharmaceutical composition
kinase inhibitors
derivatives containing
jak3 kinase
Prior art date
Application number
BR112012010186A
Other languages
English (en)
Other versions
BR112012010186B1 (pt
BR112012010186A2 (pt
Inventor
Almansa Rosales Carmen
Salas Solana Jorge
Cristina Sicre Gonzáles Maria
Soliva Soliva Robert
Rodríguez Escrich Sergio
Original Assignee
Palau Pharma Sa
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palau Pharma Sa, Vectura Ltd filed Critical Palau Pharma Sa
Publication of BR112012010186A2 publication Critical patent/BR112012010186A2/pt
Publication of BR112012010186B1 publication Critical patent/BR112012010186B1/pt
Publication of BR112012010186B8 publication Critical patent/BR112012010186B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

derivados de heteroarila contendo n como inibidores de quinase jak3. a presente invenção refere-se a derivados de heteroarila contendo n de fórmula i ou ii, em que os significados para os vários substituintes são conforme divulgado na descrição. esses compostos são úteis como inibidores de quinase jak, particularmente jak3.
BR112012010186A 2009-10-29 2010-10-29 derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos BR112012010186B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP09382233.6 2009-10-29
EP09382233 2009-10-29
US29105109P 2009-12-30 2009-12-30
US61/291,051 2009-12-30
US32992710P 2010-04-30 2010-04-30
US61/329,927 2010-04-30
PCT/EP2010/066476 WO2011051452A1 (en) 2009-10-29 2010-10-29 N-containing heteroaryl derivatives as jak3 kinase inhibitors

Publications (3)

Publication Number Publication Date
BR112012010186A2 BR112012010186A2 (pt) 2016-04-19
BR112012010186B1 BR112012010186B1 (pt) 2020-11-03
BR112012010186B8 true BR112012010186B8 (pt) 2021-05-25

Family

ID=41571618

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012010186A BR112012010186B8 (pt) 2009-10-29 2010-10-29 derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos

Country Status (23)

Country Link
US (2) US8501735B2 (pt)
EP (1) EP2493895B1 (pt)
JP (1) JP5759471B2 (pt)
KR (1) KR101675614B1 (pt)
CN (1) CN102712658B (pt)
AR (1) AR078833A1 (pt)
AU (1) AU2010311378B2 (pt)
BR (1) BR112012010186B8 (pt)
CA (1) CA2778680C (pt)
DK (1) DK2493895T3 (pt)
ES (1) ES2629006T3 (pt)
HK (1) HK1172327A1 (pt)
IL (1) IL219385A0 (pt)
MX (1) MX2012005100A (pt)
PE (1) PE20121352A1 (pt)
PL (1) PL2493895T3 (pt)
PT (1) PT2493895T (pt)
RU (1) RU2553681C2 (pt)
SI (1) SI2493895T1 (pt)
TW (1) TWI478714B (pt)
UA (1) UA109775C2 (pt)
WO (1) WO2011051452A1 (pt)
ZA (1) ZA201203090B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
EP2397482A1 (en) * 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
WO2012003576A1 (en) * 2010-07-06 2012-01-12 Université de Montréal Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
US9018395B2 (en) 2011-01-27 2015-04-28 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
WO2013025628A1 (en) * 2011-08-15 2013-02-21 Ligand Pharmaceuticals Incorporated Janus kinase inhibitor compounds and methods
CN104053661B (zh) 2011-11-23 2018-06-19 癌症研究技术有限公司 非典型性蛋白激酶c的噻吩并嘧啶类抑制剂
UY34616A (es) * 2012-02-10 2013-09-30 Galapagos Nv Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
WO2013117649A1 (en) * 2012-02-10 2013-08-15 Galapagos Nv Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases
TW201513861A (zh) * 2013-01-17 2015-04-16 Galapagos Nv 用於治療退化性及發炎疾病之新穎化合物
WO2014145852A2 (en) 2013-03-15 2014-09-18 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
US9067914B1 (en) 2013-12-10 2015-06-30 Genzyme Corporation Tropomyosin-related kinase (TRK) inhibitors
TWI705967B (zh) 2014-03-20 2020-10-01 美商卡佩拉醫療公司 苯并咪唑衍生物及其醫藥組合物及使用方法
ES2749103T3 (es) 2014-09-12 2020-03-19 Knopp Biosciences Llc Benzoimidazol-1,2-ilamidas como activadores del canal Kv7
CA2970938C (en) 2014-12-18 2023-04-18 Genzyme Corporation Pharmaceutical formulations of tropomyosin-related kinase (trk) inhibitors
EP3053927A1 (en) * 2015-02-05 2016-08-10 Vectura Limited Novel polymorphs
US10155757B2 (en) 2015-03-10 2018-12-18 Vectura Limited Crystalline form of a JAK3 kinase inhibitor
CA3005353A1 (en) 2015-11-20 2017-05-26 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
US11180480B2 (en) 2017-10-17 2021-11-23 Sensorion Synthesis of 4-aminopyrimidine compounds
TWI820146B (zh) 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN112724133B (zh) * 2021-01-12 2022-03-25 湖南复瑞生物医药技术有限责任公司 6-溴吡唑并[1,5-a]吡啶的制备方法
WO2023248010A2 (en) 2022-06-23 2023-12-28 Synovo Gmbh Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases
US20240261224A1 (en) 2022-12-02 2024-08-08 Kinaset Therapeutics, Inc. Formulation of a pan-jak inhibitor

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
AU2003278088A1 (en) 2002-10-28 2004-05-25 Bayer Healthcare Ag Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
EP1505064A1 (en) 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
AR050188A1 (es) * 2004-08-03 2006-10-04 Uriach Y Compania S A J Compuestos heterociclicos condensados utiles en terapia como inhibidores de quinasas p38 y composiciones farmaceuticas que los contienen
EP1790650B1 (en) * 2004-08-31 2014-03-26 Msd Kk NEW SUBSTITUTED IMIDAZOLE DERIVATIVES
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
JP2008534689A (ja) 2005-04-05 2008-08-28 ファーマコペイア， インコーポレイテッド 免疫抑制のためのプリン及びイミダゾピリジン誘導体
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
KR20080004585A (ko) 2005-04-08 2008-01-09 바이엘 파마슈티칼스 코포레이션 피리미딘 유도체 및 암의 치료에서의 이의 용도
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
SG151327A1 (en) * 2005-09-30 2009-04-30 Vertex Pharmaceuticals Incopor Deazapurines useful as inhibitors of janus kinases
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200831104A (en) * 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7915268B2 (en) 2006-10-04 2011-03-29 Wyeth Llc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
ES2627352T3 (es) 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
CN101595110A (zh) 2006-11-16 2009-12-02 法马科皮亚有限公司 用于免疫抑制的7-取代嘌呤衍生物
RU2009140319A (ru) * 2007-04-02 2011-05-10 Палау Фарма С.А. (Es) Производные пирролпиримидина
CN101679412A (zh) 2007-05-23 2010-03-24 药典有限责任公司 作为PKC-θ抑制剂的嘌呤酮类和1H-咪唑并吡啶酮类
US8648069B2 (en) * 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
WO2009048474A1 (en) 2007-10-12 2009-04-16 Pharmacopeia, Inc. 2,7,9-substituted purinone derivatives for immunosuppression
PE20091035A1 (es) 2007-11-30 2009-07-16 Palau Pharma Sa Derivados de 2-aminopirimidina
WO2009077608A1 (en) 2007-12-19 2009-06-25 Palau Pharma, S. A. 2 -aminopyrimidine derivatives as histamine h4 antagonists
ES2430210T3 (es) 2007-12-21 2013-11-19 Palau Pharma, S.A. Derivados de 4-aminopirimidina como antagonistas del receptor de histamina H4
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
MX345142B (es) 2009-12-23 2017-01-18 Palau Pharma Sa Derivados de aminoalquilpirimidina como antagonistas del receptor h4 de histamina.
JP2011136925A (ja) * 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物

Also Published As

Publication number Publication date
WO2011051452A1 (en) 2011-05-05
DK2493895T3 (en) 2017-08-14
EP2493895B1 (en) 2017-04-26
US20120245140A1 (en) 2012-09-27
AU2010311378A1 (en) 2012-05-24
JP2013509382A (ja) 2013-03-14
SI2493895T1 (sl) 2017-10-30
RU2553681C2 (ru) 2015-06-20
JP5759471B2 (ja) 2015-08-05
ZA201203090B (en) 2013-09-25
CA2778680A1 (en) 2011-05-05
ES2629006T3 (es) 2017-08-07
BR112012010186B1 (pt) 2020-11-03
CN102712658A (zh) 2012-10-03
CN102712658B (zh) 2015-06-03
PE20121352A1 (es) 2012-10-15
TWI478714B (zh) 2015-04-01
EP2493895A1 (en) 2012-09-05
AU2010311378B2 (en) 2014-04-24
AR078833A1 (es) 2011-12-07
BR112012010186A2 (pt) 2016-04-19
UA109775C2 (xx) 2015-10-12
RU2012122020A (ru) 2013-12-10
PT2493895T (pt) 2017-07-05
PL2493895T3 (pl) 2017-10-31
MX2012005100A (es) 2012-06-08
CA2778680C (en) 2016-12-13
TW201127385A (en) 2011-08-16
KR101675614B1 (ko) 2016-11-11
KR20120101402A (ko) 2012-09-13
US20130131038A9 (en) 2013-05-23
US8946257B2 (en) 2015-02-03
US8501735B2 (en) 2013-08-06
US20130289015A1 (en) 2013-10-31
IL219385A0 (en) 2012-06-28
HK1172327A1 (en) 2013-04-19

Similar Documents

Publication Publication Date Title
BR112012010186B8 (pt) derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos
CR20170367A (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
BR112012029647A2 (pt) novos derivados de pirimidinas
BR112014005226A2 (pt) derivados de benzonitrila como inibidores de cinase
BR112012030923B8 (pt) Composto derivado de piperidinona como inibidor de mdm2 e composição farmacêutica compreendendo o mesmo
GEP20146072B (en) New compounds
MX2013009873A (es) Inhibidores triciclicos de cinasas.
PH12015502047A1 (en) Novel pyrimidine and pyridine compounds and their usage
BR112015004113A2 (pt) 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
BRPI0910388A2 (pt) agentes terapêutico antivirais.
CO6470845A2 (es) Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
MX347241B (es) Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
MX2011005934A (es) Compuestos organicos.
IN2014CN04530A (pt)
BR112014002675A2 (pt) "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
CY1116775T1 (el) Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης
BR112015010221A2 (pt) inibidores de cinase alk
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto
MX2013001361A (es) 4-(1h-indol-3-il) - pirimidina como inhibidores de alk.
EA201200471A1 (ru) Простые эфирные производные бициклических гетероарилов
EA201590250A1 (ru) Производные карбамат/мочевины
PL401473A1 (pl) Nowe, silnie fluorescencyjne substancje heterocykliczne i sposób ich otrzymywania

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: VECTURA LIMITED (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/10/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF